en.aazsante.fr

The Largest Portal Of Health And Quality Of Life.

New test drug may inhibit Alzheimer's protein

New test drug may inhibit Alzheimer's protein

In a survey conducted by the research laboratory A new drug was discovered that could inhibit senile plaques in the brain that would lead to Alzheimer's. The results were published in the journal " Science Translational Medicine ."

The large accumulation of beta-amyloid protein is known to be one of the factors that lead to disease, creating plaques in the brain. The new drug, called verubecestat, works to reduce these plaques, acting directly on the enzyme BACE1, responsible for the appearance of beta-amyloid. Preliminary tests, performed with 32 patients, showed a reduction of up to 80% in levels of this protein. This is not the first time they have tried to create a drug with this function, but so far, all drugs created have had serious adverse effects on patients.

For the first time an oral BACE1 inhibitor drug has been authorized for a new phase involving many patients: about 3,500. Phase 3 of the research should be completed by July 2017 and, if the results remain satisfactory, the pill may be marketed within three years.


Health Department investigates case suspected of yellow fever in DF

Health Department investigates case suspected of yellow fever in DF

The Federal District Health Department is investigating a suspected case of yellow fever. The patient was a 43-year-old man from the Southwest who, in recent days, circulated in condominiums and in the rural area of ​​the Botanical Garden. According to the folder, the clinical exams performed so far have not been conclusive.

(Health)

Delay in breast cancer treatment reduces life expectancy

Delay in breast cancer treatment reduces life expectancy

Journal of Clinical Oncology . For this, 1,786 women enrolled in the health system North Carolina Medicaid diagnosed with cancer of between January 2000 and December 2002. All were followed up until July 2006. The median time between biopsy diagnosis and initiation of treatment was 22 days. Of the total, 66% started treatment within 30 days and 90% within 60 days.

(Health)